Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Horby et al., The Lancet Diabetes & Endocrinology, doi:10.1016/S2213-8587(23)00253-X
https://c19early.org/horby4.html